The Cardiovascular Research Foundation’s annual TCT conference serves as the premier cardiovascular event of the year: delivering the latest clinical and preclinical updates on a wide spectrum of transcatheter therapies and the 2016 edition was no exception.

In addition to catching up with existing and prospective sponsors and FDA regulators, here are a few of the highlights and insights from TCT 2016 in Washington, October 29 – November 2 courtesy of Preclinical Testing Program Manager Deepal Panchal.

Live aortic valve replacements & mitral valve replacement technologies
We observed a fascinating live aortic valve replacement in one of the live case sessions. Observing the embolization in a real time, live case was a very humbling experience and a reminder that transcatheter therapies have room for improvement in sizing and deployment. We want to work with sponsors to help solve those issues via preclinical testing (both GLP and non-GLP), design and development along with our partner GCMI, the Global Center for Medical Innovation.

You could hardly turn a corner or enter a session without mention of, or seeing, transcatheter mitral and aortic valve replacement technologies. The market for existing and nascent technologies appears quite healthy indeed.

Interest in Bioresorbable scaffolds
Managing coronary artery disease with conventional drug eluting metallic stents versus bioresorbable scaffolds continues to be a hot topic in the industry. Complexity of lesions, target vessel revascularization, subacute, late and very late thrombosis, vasomotor reactivity, in-segment late loss and major adverse cardiac events ; were all topics of much discussion and news at the conference.
These discussions and results underscore the importance of thorough, high-quality preclinical studies in the development of novel, complicated technologies in healthy and diseased models.

You need a trusted partner in preclinical and surgical training for novel and iterative cardiothoracic devices including TCT.
We know well the challenges of bringing new medical technologies from concept to cure to commercialization. This is why we provide the highest value preclinical testing and training services available delivering models, protocols, development insights, reliable data sets and more to support product refinements, preparedness for regulatory approvals or other inflection points that minimize the number of “$1,000 days” and maximize the value of investment in innovation for medtech companies of all shapes and sizes.

Talking about an investigative preclinical study performed at T3 Labs, Jeff Benham, staff research scientist, preclinical research and biocompatibility for Abbott Vascular said, “The Absorb BVS vasomotion (preclinical) study is an important evaluation of the benefits of a bioresorbable coronary scaffold.” A four-year study, such as this one, requires a lot of coordination, organization and thoughtfulness. The staff at T3 Labs was extremely helpful and adaptable over the course of this study, providing or locating the expertise needed to fulfill the complex technical requirements. T3 Labs was a great partner and collaborator.”

If you are evaluating the viability of a novel medical device or product for the cardiothoracic market, are ready for preclinical testing, or seeking the best training for your physicians, surgeons or sales teams, T3 Labs is a full service CRO that provides an efficient experience for preclinical testing and training. We are committed to excellence in every facet of translational research, including cardiology. This is why industry leaders like Abbott Vascular, CardioMEMS, ALung Technologies and dozens of others rely on T3 Labs for their preclinical testing and training needs.

“Programs at T3 Labs are professionally composed, orchestrated, and performed at a high level of value,” says Marc Bolton, Clinical Education Manager for Applied Medical. “I need a facility with reliable, knowledgeable scientific experts on staff and equipment that replicates a surgeon’s experience, when it matters most, in the OR.”

Contact Program Manager Deepal Panchal or call (404) 251-0634.